Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 1,400 shares, a drop of 26.3% from the December 15th total of 1,900 shares. Based on an average daily trading volume, of 9,000 shares, the days-to-cover ratio is currently 0.2 days.
Algernon Pharmaceuticals Price Performance
Shares of OTCMKTS AGNPF opened at $1.64 on Thursday. Algernon Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $9.28. The stock's 50-day simple moving average is $1.90 and its 200-day simple moving average is $2.63.
Get
Algernon Pharmaceuticals alerts:
Algernon Pharmaceuticals Company Profile
(Get Rating)
Algernon Pharmaceuticals Inc operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada, Australia, and New Zealand.
Featured Stories
- Get a free copy of the StockNews.com research report on Algernon Pharmaceuticals (AGNPF)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
阿尔杰农制药有限公司(场外交易代码:AGNPF-GET评级)是空头股数12月份大幅下跌的目标。截至12月30日,空头股数共有1,400股,比12月15日的1,900股减少了26.3%。以日均成交量9,000股计算,目前天数与回补比率为0.2天。
Algernon制药公司的价格表现
周四,OTCMKTS AGNPF的股价开盘报1.64美元。Algernon PharmPharmticals的一年低点为1.52美元,一年高位为9.28美元。该股的50日简单移动均线切入位为1.90美元,200日简单移动均线切入位为2.63美元。
到达
阿尔杰农制药公司警报:
Algernon制药公司简介
(获取评级)
Algernon制药公司是一家临床阶段药物开发公司。它集中在加拿大、澳大利亚和新西兰的非酒精性脂肪性肝炎、慢性肾脏疾病、炎症性肠道疾病、特发性肺纤维化、慢性咳嗽、胰腺癌和小细胞肺癌以及急性肺损伤等领域。
专题报道
- 免费获取StockNews.com关于Algernon制药的研究报告(AGNPF)
- 宝洁收益:一场值得冒险的赌博
- 股市下滑,经济报告为经济描绘黯淡图景
- 如新控股股票与沃伦·巴菲特有什么关系?
- J.B.亨特买房,物流公司成为焦点
- 英特尔股票是否即将突破?
获得Algernon PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Algernon制药和相关公司的最新新闻和分析师评级的每日简要摘要。